Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 2341 to 2348 of 2348 entries
Sorted by: Best Match Show Resources per page
Crowdsourced health research studies: an important emerging complement to clinical trials in the public health research ecosystem.

Journal of medical Internet research

Swan M.
PMID: 22397809
J Med Internet Res. 2012 Mar 07;14(2):e46. doi: 10.2196/jmir.1988.

BACKGROUND: Crowdsourced health research studies are the nexus of three contemporary trends: 1) citizen science (non-professionally trained individuals conducting science-related activities); 2) crowdsourcing (use of web-based technologies to recruit project participants); and 3) medicine 2.0 / health 2.0 (active...

Cite
Swan M. Crowdsourced health research studies: an important emerging complement to clinical trials in the public health research ecosystem. J Med Internet Res. 2012;14(2):e46doi: 10.2196/jmir.1988.
Swan, M. (2012). Crowdsourced health research studies: an important emerging complement to clinical trials in the public health research ecosystem. Journal of medical Internet research, 14(2), e46. https://doi.org/10.2196/jmir.1988
Swan, Melanie. "Crowdsourced health research studies: an important emerging complement to clinical trials in the public health research ecosystem." Journal of medical Internet research vol. 14,2 (2012): e46. doi: https://doi.org/10.2196/jmir.1988
Swan M. Crowdsourced health research studies: an important emerging complement to clinical trials in the public health research ecosystem. J Med Internet Res. 2012 Mar 07;14(2):e46. doi: 10.2196/jmir.1988. PMID: 22397809; PMCID: PMC3376509.
Copy Download .nbib Format: NLM
Impact of the COVID-19 Pandemic on Cancer Clinical Trials.

Annals of surgical oncology

Boughey JC, Snyder RA, Kantor O, Zheng L, Chawla A, Nguyen TT, Hillman SL, Hahn OM, Mandrekar SJ, Roland CL.
PMID: 34236550
Ann Surg Oncol. 2021 Nov;28(12):7311-7316. doi: 10.1245/s10434-021-10406-2. Epub 2021 Jul 08.

The COVID-19 pandemic has had widespread impact on healthcare, resulting in modifications to how we perform cancer research, including clinical trials for cancer. The impact of some healthcare workers and study coordinators working remotely and patients minimizing visits to...

Cite
Boughey JC, Snyder RA, Kantor O, et al. Impact of the COVID-19 Pandemic on Cancer Clinical Trials. Ann Surg Oncol. 2021;28(12):7311-7316doi: 10.1245/s10434-021-10406-2.
Boughey, J. C., Snyder, R. A., Kantor, O., Zheng, L., Chawla, A., Nguyen, T. T., Hillman, S. L., Hahn, O. M., Mandrekar, S. J., & Roland, C. L. (2021). Impact of the COVID-19 Pandemic on Cancer Clinical Trials. Annals of surgical oncology, 28(12), 7311-7316. https://doi.org/10.1245/s10434-021-10406-2
Boughey, Judy C, et al. "Impact of the COVID-19 Pandemic on Cancer Clinical Trials." Annals of surgical oncology vol. 28,12 (2021): 7311-7316. doi: https://doi.org/10.1245/s10434-021-10406-2
Boughey JC, Snyder RA, Kantor O, Zheng L, Chawla A, Nguyen TT, Hillman SL, Hahn OM, Mandrekar SJ, Roland CL. Impact of the COVID-19 Pandemic on Cancer Clinical Trials. Ann Surg Oncol. 2021 Nov;28(12):7311-7316. doi: 10.1245/s10434-021-10406-2. Epub 2021 Jul 08. PMID: 34236550; PMCID: PMC8265286.
Copy Download .nbib Format: NLM
Current and future drug-eluting coronary stent technology.

Expert review of cardiovascular therapy

Ielasi A, Latib A, Colombo A.
PMID: 21517732
Expert Rev Cardiovasc Ther. 2011 Apr;9(4):485-503. doi: 10.1586/erc.11.5.

Despite the impressive benefits obtained following the introduction of the drug-eluting stent, safety concerns have been raised over their long-term safety with particular regard to stent thrombosis. Various mechanisms such as delayed endothelialization, local hypersensitivity and endothelial dysfunction owing...

Cite
Ielasi A, Latib A, Colombo A. Current and future drug-eluting coronary stent technology. Expert Rev Cardiovasc Ther. 2011;9(4):485-503doi: 10.1586/erc.11.5.
Ielasi, A., Latib, A., & Colombo, A. (2011). Current and future drug-eluting coronary stent technology. Expert review of cardiovascular therapy, 9(4), 485-503. https://doi.org/10.1586/erc.11.5
Ielasi, Alfonso, et al. "Current and future drug-eluting coronary stent technology." Expert review of cardiovascular therapy vol. 9,4 (2011): 485-503. doi: https://doi.org/10.1586/erc.11.5
Ielasi A, Latib A, Colombo A. Current and future drug-eluting coronary stent technology. Expert Rev Cardiovasc Ther. 2011 Apr;9(4):485-503. doi: 10.1586/erc.11.5. PMID: 21517732.
Copy Download .nbib Format: NLM
Science and Evidence-Based Review and Approval of COVID-19 Vaccines: A Statement of Support for the US FDA.

Journal of clinical pharmacology

Pai SM, Othman AA, Rusch L, Masters JC, Greene D, Rogge M, Gries JM, Clementi W, Kumar P, Younis I, Salem AH, Gaynes BI, Pastino G, Derendorf H.
PMID: 33274473
J Clin Pharmacol. 2021 Mar;61(3):277-279. doi: 10.1002/jcph.1794. Epub 2021 Jan 27.

No abstract available.

Cite
Pai SM, Othman AA, Rusch L, et al. Science and Evidence-Based Review and Approval of COVID-19 Vaccines: A Statement of Support for the US FDA. J Clin Pharmacol. 2021;61(3):277-279doi: 10.1002/jcph.1794.
Pai, S. M., Othman, A. A., Rusch, L., Masters, J. C., Greene, D., Rogge, M., Gries, J. M., Clementi, W., Kumar, P., Younis, I., Salem, A. H., Gaynes, B. I., Pastino, G., Derendorf, H. (2021). Science and Evidence-Based Review and Approval of COVID-19 Vaccines: A Statement of Support for the US FDA. Journal of clinical pharmacology, 61(3), 277-279. https://doi.org/10.1002/jcph.1794
Pai, Sudhakar M, et al. "Science and Evidence-Based Review and Approval of COVID-19 Vaccines: A Statement of Support for the US FDA." Journal of clinical pharmacology vol. 61,3 (2021): 277-279. doi: https://doi.org/10.1002/jcph.1794
Pai SM, Othman AA, Rusch L, Masters JC, Greene D, Rogge M, Gries JM, Clementi W, Kumar P, Younis I, Salem AH, Gaynes BI, Pastino G, Derendorf H. Science and Evidence-Based Review and Approval of COVID-19 Vaccines: A Statement of Support for the US FDA. J Clin Pharmacol. 2021 Mar;61(3):277-279. doi: 10.1002/jcph.1794. Epub 2021 Jan 27. PMID: 33274473; PMCID: PMC7754558.
Copy Download .nbib Format: NLM
Evidence in oncology. The Janeway lecture 2000.

Cancer journal (Sudbury, Mass.)

Cox JD.
PMID: 11131481
Cancer J. 2000 Nov-Dec;6(6):351-7.

PURPOSE: The purpose of this address is to evaluate the types of evidence that have fashioned clinical decision making in oncology over the past century and to determine the appropriate weighting of evidence at the start of a new...

Cite
Cox JD. Evidence in oncology. The Janeway lecture 2000. Cancer J. 2000;6(6):351-7
Cox, J. D. (2000). Evidence in oncology. The Janeway lecture 2000. Cancer journal (Sudbury, Mass.), 6(6), 351-7.
Cox, J D. "Evidence in oncology. The Janeway lecture 2000." Cancer journal (Sudbury, Mass.) vol. 6,6 (2000): 351-7.
Cox JD. Evidence in oncology. The Janeway lecture 2000. Cancer J. 2000 Nov-Dec;6(6):351-7. PMID: 11131481.
Copy Download .nbib Format: NLM
Time for N-of-1 trials in clinical decision-making.

Brain : a journal of neurology

Husain M.
PMID: 33871604
Brain. 2021 May 07;144(4):1031-1032. doi: 10.1093/brain/awab107.

No abstract available.

Cite
Husain M. Time for N-of-1 trials in clinical decision-making. Brain. 2021;144(4):1031-1032doi: 10.1093/brain/awab107.
Husain, M. (2021). Time for N-of-1 trials in clinical decision-making. Brain : a journal of neurology, 144(4), 1031-1032. https://doi.org/10.1093/brain/awab107
Husain, Masud. "Time for N-of-1 trials in clinical decision-making." Brain : a journal of neurology vol. 144,4 (2021): 1031-1032. doi: https://doi.org/10.1093/brain/awab107
Husain M. Time for N-of-1 trials in clinical decision-making. Brain. 2021 May 07;144(4):1031-1032. doi: 10.1093/brain/awab107. PMID: 33871604.
Copy Download .nbib Format: NLM
Functional studies of GWAS variants are gaining momentum.

Nature communications

Lichou F, Trynka G.
PMID: 33293539
Nat Commun. 2020 Dec 08;11(1):6283. doi: 10.1038/s41467-020-20188-y.

No abstract available.

Cite
Lichou F, Trynka G. Functional studies of GWAS variants are gaining momentum. Nat Commun. 2020;11(1):6283doi: 10.1038/s41467-020-20188-y.
Lichou, F., & Trynka, G. (2020). Functional studies of GWAS variants are gaining momentum. Nature communications, 11(1), 6283. https://doi.org/10.1038/s41467-020-20188-y
Lichou, Florence, and Trynka, Gosia. "Functional studies of GWAS variants are gaining momentum." Nature communications vol. 11,1 (2020): 6283. doi: https://doi.org/10.1038/s41467-020-20188-y
Lichou F, Trynka G. Functional studies of GWAS variants are gaining momentum. Nat Commun. 2020 Dec 08;11(1):6283. doi: 10.1038/s41467-020-20188-y. PMID: 33293539; PMCID: PMC7722852.
Copy Download .nbib Format: NLM
Current strategies of virotherapy in clinical trials for cancer treatment.

Journal of medical virology

Lin W, Zhao Y, Zhong L.
PMID: 33738818
J Med Virol. 2021 Aug;93(8):4668-4692. doi: 10.1002/jmv.26947. Epub 2021 Apr 23.

As a novel immune-active agent for cancer treatment, viruses have the ability of infecting and replicating in tumor cells. The safety and efficacy of viruses has been tested and confirmed in preclinical and clinical trials. In the last decade,...

Cite
Lin W, Zhao Y, Zhong L. Current strategies of virotherapy in clinical trials for cancer treatment. J Med Virol. 2021;93(8):4668-4692doi: 10.1002/jmv.26947.
Lin, W., Zhao, Y., & Zhong, L. (2021). Current strategies of virotherapy in clinical trials for cancer treatment. Journal of medical virology, 93(8), 4668-4692. https://doi.org/10.1002/jmv.26947
Lin, Weijian, et al. "Current strategies of virotherapy in clinical trials for cancer treatment." Journal of medical virology vol. 93,8 (2021): 4668-4692. doi: https://doi.org/10.1002/jmv.26947
Lin W, Zhao Y, Zhong L. Current strategies of virotherapy in clinical trials for cancer treatment. J Med Virol. 2021 Aug;93(8):4668-4692. doi: 10.1002/jmv.26947. Epub 2021 Apr 23. PMID: 33738818.
Copy Download .nbib Format: NLM
Showing 2341 to 2348 of 2348 entries